NCT05478083 (AGAINST-PLD) is a Phase 2 clinical trial of Leuprorelin in Polycystic Liver Disease, sponsored by University Medical Center Groningen.

Who is sponsoring NCT05478083?

NCT05478083 is sponsored by University Medical Center Groningen.

What drugs are being tested in NCT05478083?

Interventions in NCT05478083: Leuprorelin.

What condition does NCT05478083 study?

NCT05478083 studies Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney.

Is NCT05478083 still recruiting?

NCT05478083 is currently recruiting now. Last updated 4 November 2022.

Last reviewed 2022-11-04 · How we verify

NCT05478083: AGAINST-PLD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease

Recruiting now Phase 2 Last updated 4 November 2022

What this trial tests

Phase 2 trial testing Leuprorelin in Polycystic Liver Disease in 36 participants. Currently enrolling.

Timeline

1 June 2022

Primary endpoint
1 June 2027

1 October 2027

Quick facts

Lead sponsor	University Medical Center Groningen
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	36
Start date	1 June 2022
Primary completion	1 June 2027
Estimated completion	1 October 2027
Sites	2 locations across Netherlands

Drugs / interventions tested

Leuprorelin (leuprorelin) — full drug profile →

Conditions studied

Polycystic Liver Disease — all drugs for Polycystic Liver Disease →
Autosomal Dominant Polycystic Kidney — all drugs for Autosomal Dominant Polycystic Kidney →

Sponsor

University Medical Center Groningen

Who can join

Adults 18 to 45, female only, with Polycystic Liver Disease or Autosomal Dominant Polycystic Kidney. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicenter trial on the effect of the GnRH analogue leuprorelin on the growth of total liver volume in pre-menopausal women with very severe polycystic liver disease who, despite available therapy, experience growth and are heading for liver transplantation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical manifestation, epidemiology, genetic basis, potential molecular targets, and current treatment of polycystic liver disease.
Mahboobipour AA, Ala M, Safdari Lord J, Yaghoobi A. · · 2024 · cited 7× · PMID 38671465 · DOI 10.1186/s13023-024-03187-w

Verify or expand the search:

Other trials of Leuprorelin

Trials testing the same drug.

NCT07159451 — A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovaria · Phase 2 · recruiting
NCT05206682 — Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean · NA · recruiting
NCT05440383 — A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia · Phase 3 · completed
NCT05087706 — Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS） · unknown
NCT04302454 — Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy · Phase 3 · active not recruiting

Other recruiting trials for Polycystic Liver Disease

Currently open trials in the same condition.

NCT04645251 — Polycystic Liver Disease Registry (UK) · recruiting

Other University Medical Center Groningen trials

Trials by the same sponsor.

NCT06647602 — Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy · not yet recruiting
NCT06809946 — Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy · Phase 2 · not yet recruiting
NCT07527390 — CANagliflozin In DIALysis Patients · Phase 4 · not yet recruiting
NCT07439237 — Implant-supported Maxillary Overdentures; a 15-years Evaluation · not yet recruiting
NCT07275437 — Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fra · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05478083 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medical Center Groningen
Last refreshed: 4 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05478083.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing